

NIEUWSBRIEF KLINISCHE STUDIES THORAXONCOLOGIE

JULI 2025

<https://www.uniccra.be/lung-cancer-trials/>



NIEUWE STUDIES IN DE KIJKER

PULMO-01 (iOnctura): A Phase IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in patients with advanced non-squamous NSCLC who have progressed on standard of care immune checkpoint therapy and platinum doublet chemotherapy or standard immunotherapy without chemotherapy

NSCLC, NSQ - 2/3L advanced/metastatic

DeLLphi-309 (Amgen): A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer

ED-SCLC - 2L

Tropion Lung 15 (AstraZeneca): A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment

NSCLC, EGFRm - 2L metastatic, after osimertinib

SOHO-02 (Bayer): A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with *HER2*-activating mutations

NSCLC, NSQ, HER2m - 1L advanced/metastatic

Livigno-04 (AbbVie): Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

NSCLC, NSQ - 1L metastatic

Sunray-02 (Eli Lilly): Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

stage II-IIIb resectable NSCLC- KRAS G12C - Na neoadjuvante of adjuvante therapie

Tentatieve opening van de studie: 14/07/2025

Voor meer informatie contacteer [Giete Moons](#) | [Lie Cassiers](#)

Stafliden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)

Relativity-1093 (Bristol-Myers Squibb): A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression $\geq 1\%$

NSCLC, NSQ 1L – PD-L1 $\geq 1\%$

Tentatieve opening van de studie: 14/07/2025

NIET-KLEINCELLIG LONGCARCINOOM

PACIFIC-8 (AstraZeneca): A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab in Participants with Locally Advanced (Stage III), Unresectable NSCLC Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

stage III NSCLC – na concurrente chemoradiotherapie

LUNG Platform (GSK): A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, PD-L1-Selected NSCLC

NSCLC 1L – PD-L1 $\geq 50\%$

KRYSTAL-7 (Mirati Therapeutics): A Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation.

NSCLC 1L – non-squamous – KRAS G12C + PD-L1 $\geq 50\%$

SAFFRON (AstraZeneca): A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Vs Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic NSCLC Who Have Progressed on Treatment With Osimertinib

NSCLC – EGFRm+ na osimertinib

TeliMET NSCLC-01 (AbbVie): A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous NSCLC

NSCLC 2L – non-squamous cMET overexp – nog geen docetaxel gehad

Voor meer informatie contacteer **Giete Moons** | **Lie Cassiers**

Stafleden thoraxoncologie: **Annelies Janssens** | **Jo Raskin** | **Reinier Wener** | **Mick van de Wiel**

Fase I studies: **Bernd Dekeyser**

KRASCENDO-1 (Roche): A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Divarasil Versus Sotorasil Or Adagrasil In Patients With Previously Treated KRAS G12C-Positive Advanced Or Metastatic Non-Small Cell Lung Cancer

NSCLC 2-4L – KRAS G12C

On hold

MK-2870-019 (Merck): A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

stage II-IIIb NSCLC perioperatief – inclusie na resectie mogelijk

INTerpath-002 (Merck): A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

stage II-IIIb NSCLC 1L – R0 resected

DO2.22.01 (Deuter Oncology): A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

NSCLC post SOC – METamp/METex14skipping

Momenteel geen sloten beschikbaar

21820 (Bayer): First-in-human dose-escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of the anti-CCR8 antibody BAY 3375968 as monotherapy and in combination with pembrolizumab in participants with selected advanced solid tumors

NSCLC post SOC

Momenteel geen sloten beschikbaar

20210023 (AMGEN): AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

NSCLC post SOC – squamous – MTAP-verlies

Voor meer informatie contacteer [Giete Moons](#) | [Lie Cassiers](#)

Stafleden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)

DAREON-7 (Boehringer): A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of BI 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas

LCNEC 1L – DLL3+

CDR404-001 (CDR-Life AG): A Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

*NSCLC post SOC – HLA-A*02:01-positief en MAGE-A4-positief*

JK06.1.01 (Salubris): A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NSCLC post SOC

On hold – Wachtlijst

GO43860 (Genentech): A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

NSCLC 1L

Momenteel sloten voor CPI-naïeve patiënten

KLEINCELLIG LONGCARCINOOM

PRIMALung (EORTC): PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients

LD-SCLC en ED-SCLC na (immuno)chemotherapie of chemoradiotherapie

PLEURAAL MESOTHELIOM

HiPeRMESO (Academisch): High-intensity Pleural Radiotherapy after (extended) pleurectomy and decortication in patient with pleural MESOthelioma

adjuvant mesotheliom 1L

Voor meer informatie contacteer **Giete Moons** | **Lie Cassiers**

Stafleden thoraxoncologie: **Annelies Janssens** | **Jo Raskin** | **Reinier Wener** | **Mick van de Wiel**

Fase I studies: **Bernd Dekeyser**

SOLIDE TUMOREN – PSYCHOSOCIAAL

REMOTE (Academisch) Targeting Fear of Cancer Recurrence in Cancer Survivors: a multicentre randomized controlled trial to evaluate Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as intervention strategies

Kankerpatiënten in remissie met angst voor herval

EPITHELIALE TUMOREN VAN DE THYMUS

Geen beschikbare studies

OVERZICHT VAN ALLE LOPENDE STUDIES IN BELGIË



Voor meer informatie contacteer **Giete Moons** | **Lie Cassiers**

Stafliden thoraxoncologie: **Annelies Janssens** | **Jo Raskin** | **Reinier Wener** | **Mick van de Wiel**

Fase I studies: **Bernd Dekeyser**